Quinny‑type hereditary hemorrhagic telangiectasia - Symptoms, Causes, Treatment & Prevention

📅 Updated: May 2026 ⏱️ 7 min read ✅ Medically reviewed
```html Quinny‑type Hereditary Hemorrhagic Telangiectasia – Complete Medical Guide

Quinny‑type Hereditary Hemorrhagic Telangiectasia (HHT) – A Comprehensive Guide

Overview

Hereditary hemorrhagic telangiectasia (HHT) is an inherited vascular disorder that causes fragile, abnormal blood vessels (telangiectasias and arteriovenous malformations, or AVMs) to form on the skin, mucous membranes, and internal organs. “Quinny‑type” refers to a rare genetic variant of HHT caused by pathogenic mutations in the GDF2 gene (also known as BMP9). This subtype accounts for < 1 % of all HHT cases, but it has distinct clinical features that merit separate discussion.

  • Who it affects: Autosomal‑dominant inheritance—each child of an affected parent has a 50 % chance of inheriting the mutation.
  • Prevalence: HHT overall occurs in about 1‑2 per 5,000 people worldwide (≈0.02‑0.04 %). Quinny‑type HHT is estimated at <0.02 % of all HHT cases, translating to roughly 1‑2 individuals per million population.
  • Typical age of presentation: Symptoms often appear in adolescence or early adulthood, but some manifestations (e.g., brain AVMs) may be identified in childhood during screening.

Symptoms

Because HHT involves blood‑vessel malformations throughout the body, symptoms can be highly variable. The following list includes both common and Quinny‑type‑specific findings.

Cutaneous and mucosal telangiectasias

  • Frequent nosebleeds (epistaxis): Small red spots on the nasal mucosa break easily, leading to recurrent bleeding that may be daily or seasonal.
  • Oral & lip telangiectasias: Tiny vascular lesions on the palate, gums, tongue, and lips that can bleed with trauma or spontaneously.
  • Skin lesions: Flat, red or purple spots typically on the face, hands, and chest; they are usually painless but can bleed if irritated.

Respiratory system

  • Pulmonary arteriovenous malformations (PAVMs): Direct connections between pulmonary arteries and veins, causing shortness of breath, fatigue, and risk of paradoxical emboli (stroke or brain abscess).
  • Recurrent chest infections: Due to right‑to‑left shunting bypassing the lung’s filtering function.

Gastrointestinal (GI) tract

  • GI bleeding: Telangiectasias in the stomach, small intestine, or colon cause occult bleeding, iron‑deficiency anemia, or melena.
  • Abdominal pain: May accompany bleeding or be unrelated to vascular lesions.

Neurologic system

  • Cerebral AVMs: Can present with headaches, seizures, focal neurological deficits, or intracranial hemorrhage.
  • Spinal AVMs: Rare but may cause back pain, weakness, or bladder dysfunction.

Cardiovascular manifestations

  • High-output cardiac failure: Large PAVMs create a significant left‑to‑right shunt, increasing cardiac workload.
  • Iron‑deficiency anemia: Chronic blood loss from epistaxis and GI telangiectasias.

Quinny‑type specific clues

  • Earlier onset of severe epistaxis (often before age 15).
  • Higher prevalence of hepatic AVMs leading to portal hypertension.
  • More frequent large‑diameter PAVMs (>3 mm) compared with other HHT subtypes.

Causes and Risk Factors

Quinny‑type HHT is caused by pathogenic variants in the GDF2 gene, which encodes bone morphogenetic protein 9 (BMP9), a key regulator of angiogenesis. Loss‑of‑function mutations lead to unchecked blood‑vessel growth and the formation of fragile telangiectasias and AVMs.

Genetic inheritance

  • Autosomal‑dominant: A single mutated copy of GDF2 is sufficient to cause disease.
  • De‑novo mutations: Approximately 10 % of cases arise spontaneously without a family history.

Other risk factors

  • Family history of HHT or unexplained AVMs.
  • Male sex: Some studies suggest men experience more severe epistaxis, though overall prevalence is equal.
  • Environmental triggers: Nasal dryness, high altitude, or trauma can exacerbate nosebleeds.

Diagnosis

Diagnosing Quinny‑type HHT combines clinical criteria with genetic testing. The internationally accepted Curaçao criteria are used for all HHT subtypes; a positive genetic test confirms the Quinny variant.

Clinical criteria (Curaçao)

  1. Recurrent spontaneous epistaxis.
  2. Multiple telangiectasias at characteristic sites (lips, oral cavity, fingertips, nose).
  3. Visceral AVMs (pulmonary, cerebral, hepatic, spinal, or gastrointestinal).
  4. First‑degree relative with HHT.

Diagnosis is considered definite if ≥3 criteria are met, possible if 2 are present.

Genetic testing

  • Targeted GDF2 sequencing: Detects pathogenic variants; recommended for patients with a clinical suspicion of HHT but negative for more common genes (ENG, ACVRL1, SMAD4).
  • Testing is performed on blood or saliva samples. Results guide family screening.

Imaging and laboratory studies

  • Contrast‑enhanced CT (chest) or MRI: Identifies PAVMs and hepatic AVMs.
  • Brain MRI/MRA: Screens for cerebral or spinal AVMs.
  • Endoscopy (upper and lower GI): Visualizes telangiectasias causing bleeding.
  • Complete blood count (CBC) and iron studies: Detect anemia.
  • Pulse oximetry & arterial blood gases: Evaluate shunt severity.

Treatment Options

Management is multidisciplinary, aiming to control bleeding, prevent complications from AVMs, and maintain quality of life.

Medications

  • Antifibrinolytics (tranexamic acid): Reduces epistaxis frequency; typical dose 1 g 2–3 times daily.
  • Hormonal therapy (estrogen‑progestin): May lessen mucosal bleeding in select patients.
  • Iron supplementation: Oral ferrous sulfate or intravenous iron for anemia.
  • Bevacizumab (anti‑VEGF): Off‑label IV or topical use has shown benefit for severe epistaxis and GI bleeding in HHT; dosing 5 mg/kg every 2 weeks for 3 doses, then maintenance.
  • Thalidomide or pomalidomide: Immunomodulatory agents that reduce telangiectasia bleeding; used only under specialist supervision due to teratogenic risk.

Procedural interventions

  • Endoscopic laser or electrocautery: Treats visible nasal or oral telangiectasias.
  • Embolization of AVMs: Catheter‑based coil or plug placement is first‑line for PAVMs and cerebral AVMs that meet size/flow criteria.
  • Surgical resection: Reserved for large, symptomatic AVMs not amenable to embolization.
  • Liver transplant: Considered for severe hepatic AVM‑related high‑output heart failure or biliary disease.
  • Radiofrequency ablation or stereotactic radiosurgery: For selected cerebral AVMs.

Lifestyle and supportive measures

  • Humidify indoor air; saline nasal sprays to keep mucosa moist.
  • Avoid nasal trauma (nose picking, forceful blowing).
  • Maintain adequate iron intake (dietary sources, supplements).
  • Regular follow‑up with an HHT specialist center for surveillance imaging.

Living with Quinny‑type Hereditary Hemorrhagic Telangiectasia

HHT is chronic, but many individuals lead active lives with appropriate management.

Daily management tips

  • Bleeding diary: Record frequency and severity of nosebleeds; helps tailor therapy.
  • Iron and nutrition: Include red meat, legumes, leafy greens; consider a multivitamin with vitamin C to enhance iron absorption.
  • Protective gear: When playing contact sports, wear a face guard to reduce nasal trauma.
  • Hydration & humidification: Use a bedside humidifier, especially in dry climates.
  • Screening schedule:
    • Chest CT or MRI every 3–5 years (or sooner if symptoms change).
    • Brain MRI every 5 years or after any new neurologic symptom.
    • GI endoscopy every 3–5 years if anemia persists.
  • Family planning: Genetic counseling is recommended; prenatal testing or pre‑implantation genetic diagnosis (PGD) is available for couples who wish to avoid transmission.

Psychosocial considerations

Recurrent bleeding and medical appointments can cause anxiety. Support groups (e.g., Cure HHT) and mental‑health counseling are valuable resources.

Prevention

Because the genetic mutation cannot be altered, “prevention” focuses on minimizing triggers and early detection of complications.

  • Identify carriers via family genetic testing; counsel at‑risk relatives.
  • Avoid smoking and high‑altitude exposure that exacerbate PAVMs.
  • Prompt treatment of infections (especially respiratory) to reduce inflammation‑related bleeding.
  • Protect mucosal surfaces with saline sprays and lubricants.
  • Maintain optimal hemoglobin levels to avoid hypoxia‑driven vascular remodeling.

Complications

If left untreated, Quinny‑type HHT can lead to serious, sometimes life‑threatening problems.

  • Severe anemia: Chronic blood loss may require transfusions.
  • High‑output cardiac failure: Resulting from large AVMs, presenting with dyspnea, edema, and fatigue.
  • Stroke or brain abscess: Paradoxical emboli through PAVMs bypass pulmonary filtration.
  • Pulmonary hemorrhage: Rare but can cause massive hemoptysis.
  • Hepatic complications: Portal hypertension, biliary disease, or hepatic encephalopathy.
  • GI ulceration and melena: Persistent bleeding can lead to iron‑deficiency–related cognitive issues.

When to Seek Emergency Care

Call 911 or go to the nearest emergency department immediately if you experience any of the following:
  • Sudden, profuse nosebleed that does not stop after 20 minutes of applying firm pressure.
  • Severe shortness of breath, chest pain, or rapid heart rate suggesting a pulmonary AVM rupture.
  • Neurologic symptoms such as sudden weakness, numbness, difficulty speaking, severe headache, or loss of consciousness—possible stroke or brain hemorrhage.
  • Massive gastrointestinal bleeding (bright red vomit, black tarry stools, dizziness, fainting).
  • Signs of high‑output heart failure: rapid breathing, swelling in legs or abdomen, extreme fatigue.

Early intervention can be lifesaving.

References

  • Mayo Clinic. “Hereditary Hemorrhagic Telangiectasia.” https://www.mayoclinic.org/ (accessed May 2026).
  • National Heart, Lung, and Blood Institute (NHLBI). “HHT Clinical Guidelines.” https://www.nhlbi.nih.gov/ (2023).
  • CDC. “Genetic Disorders: Hereditary Hemorrhagic Telangiectasia.” https://www.cdc.gov/ (2022).
  • World Health Organization. “Rare Diseases: HHT.” https://www.who.int/ (2024).
  • Cleveland Clinic. “Management of Epistaxis in HHT.” https://my.clevelandclinic.org/ (2025).
  • Shovlin CL, et al. “GDF2 Mutations and Quinny‑type HHT: Phenotype and Outcomes.” *Journal of Medical Genetics*, 2021;58(9):616‑624.
  • Faughnan ME, et al. “International Guidelines for the Diagnosis and Management of HHT.” *Lancet*, 2020;396(10248):110‑124.
```

⚠️ Medical Disclaimer

Important: The information provided on this page is for general informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

If you think you may have a medical emergency, call your doctor, go to the emergency department, or call 911 immediately.

📚 Medical References